Since 1991, AGITG have been committed to changing outcomes for people with cancers of the digestive system. Their key priority is to undertake research to improve patient care and medical practice. The 60 clinical trials conducted by the AGITG, since the group was first formed as a network of investigators, have involved over 7,000 participants treated at 115 sites in Australia, 8 sites in New Zealand, and 110 sites located across Asia, Europe, North America and the Middle East.
In many ways, it was AGITG that inspired the creation of GCF. GCF was originally established to try and fill the funding gap that often prevents AGITG trials from taking place in New Zealand. This role remains a key pillar of GCF’s strategic priorities to this day.
Since GCF was established in 2008, the chair of AGITG has always sat on the GCF board. The 2 organisations have shared other board members and our teams regularly share ideas and best practices in areas such as fundraising and marketing. Members of the GCF Board and Scientific Advisory Committee have held membership and key positions within AGITG giving the 2 organisations an integral link through New Zealand’s clinical expertise.
To find out more visit: https://gicancer.org.au/about-the-agitg/